1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 71335-2625
  5. Product Images: Duloxetine

Product Images Duloxetine

View Photos of Packaging, Labels & Appearance

Table of Contents

  1. Structure - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 01
  2. Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 02
  3. Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 03
  4. Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 04
  5. Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 05
  6. fig 5 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 06
  7. fig 6 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 07
  8. Fig 7 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 08
  9. Figure 8 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 09
  10. Figure 9 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 10
  11. Figure 10 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 11
  12. Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 935 1
  13. Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 942 1
  14. Label - lbl713352625

Product Label Images

The following 14 images provide visual information about the product associated with Duloxetine NDC 71335-2625 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Structure - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 01

Structure - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 01

Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 02

Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 02

This text presents information on the proportion of patients who relapsed over time for the placebo and duloxetine treatments. The data is displayed graphically with time (in days) on the X-axis and the proportion of patients on the Y-axis. The Kaplan-Meier estimator method was used for analysis. The chart shows a decreasing trend in the relapse rate over the observed period for both treatments.*

Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 03

Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 03

This text provides data on the proportion of patients experiencing a relapse over time while being treated with either Placebo or Duloxetine. The numbers indicate the number of patients experiencing relapse at different time points after randomization. The data is likely presented using the Kaplan-Meier estimator method.*

Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 04

Figure 1 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 04

This text provides information on the percentage of patients showing improvement in pain levels when taking different doses of duloxetine and placebo. The data seems to compare the efficacy of Duloxetine 60mg, Duloxetine 20mg, and placebo in managing pain. The percentage of patients improved can help evaluate the effectiveness of these medications in pain relief.*

Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 05

Figure 2 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 05

fig 5 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 06

fig 5 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 06

Percentage of Patients Improved with Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and Placebo treatment. Improvement in pain from baseline is also shown.*

fig 6 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 07

fig 6 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 07

The text provides information on the percentage of patients improved with different treatments for pain management. It shows the comparison between Duloxetine 120mg twice daily, Duloxetine 60mg once daily, and a Placebo. The percentage of improvement in pain from the baseline is also represented in the data.*

Fig 7 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 08

Fig 7 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 08

Figure 8 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 09

Figure 8 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 09

This text provides information on the percentage of patients improved with a placebo compared to duloxetine 60/120 mg once daily. It includes a data chart showing the percent improvement in pain from baseline.*

Figure 9 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 10

Figure 9 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 10

This text provides data on the percentage of patients improved with the use of Duloxetine 60 mg compared to a placebo. It indicates that 100% of patients showed improvement with Duloxetine 60 mg compared to the placebo. The graph shows the percent improvement in pain from baseline over time with treatments.*

Figure 10 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 11

Figure 10 - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 11

This text mentions the percentage of patients improved with Duloxetine 60/120 mg compared to a placebo, with a potential improvement of 100%. It also indicates the percent improvement in pain from baseline (BOCF). This data can be helpful for understanding the efficacy of Duloxetine in treating certain conditions.*

Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 935 1

Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 935 1

Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 942 1

Image - 7ad45dfa a630 4e5f 85c0 25dc9e8bfbb7 942 1

Label - lbl713352625

Label - lbl713352625

The text provides information about a delayed-release capsule containing 67.3 mg of Duloxetine Hydrochloride USP, equivalent to 60 mg NDC 71335-2625_1. It suggests checking the package insert QR code for prescribing information and advises storing the capsules at 25°C with excursions permitted to 15° to 30°C. The text also mentions keeping the medication out of reach of children and instructs to dispense in a tightly closed container. Manufacturer information includes Bryant Ranch Prepack, Inc. and Lupin Limited.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.